SQI Diagnostics Hired by Global Pharmaceutical Company to Develop Two Prototype Multiplex Immunoassays for Evaluation

May 20, 2014

TORONTO, May 20, 2014 /PRNewswire/ – SQI Diagnostics Inc. (TSX-V: SQD), a life sciences company that develops and commercializes proprietary
technologies and products for advanced microarray diagnostics, today
announced it is being paid by one of the ten largest pharmaceutical
companies in the world to develop and validate two custom multiplex
anti-drug-antibody (“ADA”) assays. This new customer will evaluate
these two products using an established drug from its portfolio in
order to assess the capabilities and performance of SQI’s technologies.

“This is an important opportunity to establish SQI’s capabilities with
one of the largest customers in our industry, and highlights the
growing interest for our technology and its ability to make drug
development faster and more efficient,” said Andrew Morris, CEO of SQI
Diagnostics. “To date, our customer base includes four of the fifty
largest pharmaceutical and biotech companies which have contracted SQI
to develop custom assays for evaluation to facilitate their
immunogenicity testing.”

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops
and commercializes proprietary technologies and products for advanced
microarray diagnostics. The Company’s proprietary microarray tests and
fully-automated systems are designed to simplify protein and antibody
testing workflow, increase throughput, reduce costs and provide
excellent data quality. For more information, please visit www.sqidiagnostics.com.

Forward-looking Information

This news release contains certain forward-looking statements,
including, without limitation, statements containing the words “will”,
“expects”, “intends” and other similar expressions which constitute
“forward-looking information” within the meaning of applicable
securities laws. Forward-looking statements reflect the Company’s
current expectation and assumptions, and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially from those anticipated. These forward-looking statements
involve risks and uncertainties including, but not limited to risks
related to the failure to obtain necessary regulatory approvals,
general economic and market segment conditions, and international risk
and currency exchange, agreements and future agreements to sell our
products, the success of our Diagnostic Tools and Services business and
our intent to build near-term revenue streams from this business, the
successful regulatory filing and receipt of regulatory approvals for
our later stage quantitative diagnostic kits, the acceleration of our
revenue ramp, general economic and market segment conditions,
competitor activity, technology changes and regulatory approvals. Such
statements reflect the current views of the Company with respect to
future events and are subject to certain risks and uncertainties and
other risks detailed from time-to-time in the Company’s ongoing filings
with the securities regulatory authorities, which filings can be found
at www.sedar.com. Actual results, events, and performance may differ
materially. Readers are cautioned not to place undue reliance on these
forward-looking statements. The Company undertakes no obligation to
publicly update or revise any forward-looking statements either as a
result of new information, future events or otherwise, except as
required by applicable laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.

SOURCE SQI Diagnostics Inc.

Source: PR Newswire

comments powered by Disqus